Showing results (81-90 of 97) with videos related to
Sort By:
Pageof 10
Annals of Internal Medicine|December 19, 2012
Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trialAlexa B Kimball, Francisco Kerdel, David Adams, et al.Journal of Immunology (Baltimore, Md. : 1950)|April 29, 2015
Allogeneic Mature Human Dendritic Cells Generate Superior Alloreactive Regulatory T Cells in the Presence of IL-15Nicolle H R Litjens, Karin Boer, Joke M Zuijderwijk, et al.Plos One|April 13, 2011
Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasisWilliam R Swindell, Andrew Johnston, Steve Carbajal, et al.International Journal of Dermatology|March 14, 2025
Neutrophil Extracellular Traps Are Widely Distributed Across Lesional and Perilesional Hidradenitis Suppurativa Skin, and Elevated Serum NET Markers Associate With Moderate to Severe HS DiseaseStephanie C M van Dalen, Josephine W J Stein, Tirza Bruurmijn, et al.Frontiers in Immunology|August 7, 2023
Oral prednisolone suppresses skin inflammation in a healthy volunteer imiquimod challenge modelSalma Assil, Thomas P Buters, Pieter W Hameeteman, et al.Clinical and Translational Science|April 22, 2020
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II TrialTessa Niemeyer-van der Kolk, Hein van der Wall, Geretta K Hogendoorn, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|April 4, 2023
Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trialAstrid M van Huizen, Gayle E van der Kraaij, Celine I Busard, et al.Journal of the American Academy of Dermatology|October 3, 2020
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trialTessa Niemeyer-van der Kolk, Thomas P Buters, Lara Krouwels, et al.The British Journal of Dermatology|October 13, 2025
Vilobelimab to improve clinical outcomes of moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: Results of the SHINE double-blind, placebo-controlled randomised trialEvangelos J Giamarellos-Bourboulis, Gregor B E Jemec, Errol P Prens, et al.The Journal of Investigative Dermatology|September 18, 2022
Disease Association of Anti‒Carboxyethyl Lysine Autoantibodies in Hidradenitis SuppurativaGiulio Macchiarella, Vanessa Cornacchione, Celine Cojean, et al.Pageof 10